E
EO7
vs
D
DAX Index
Over the past 12 months, EO7 has underperformed DAX Index, delivering a return of 0% compared to the DAX Index's +10% growth.
Stocks Performance
EO7 vs DAX Index
Performance Gap
EO7 vs DAX Index
Performance By Year
EO7 vs DAX Index
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Endo International PLC
Glance View
Endo International PLC is a specialty pharmaceutical company that operates at the intersection of innovation and necessity within the healthcare industry. Its primary business involves developing, manufacturing, and marketing both branded and generic pharmaceutical products. Endo thrives on a diversified portfolio that spans numerous therapeutic areas, including pain management, urology, orthopedics, and endocrinology. The company strategically positions itself by addressing unmet medical needs, often targeting niche markets where the competition is minimal, thus allowing for premium pricing and robust profit margins. Endo's revenue streams are driven by a blend of proprietary and generic drugs, with a significant portion coming from its well-known brands such as PERCOCET® and SUPPRELIN® LA. Its generics division supplements this by producing cost-effective versions of popular drugs, supporting market accessibility and appealing to cost-sensitive consumers and healthcare providers. By leveraging its research and development capabilities, Endo continues to enhance its product portfolio and explore new market opportunities. The company's growth is rooted in its ability to adapt to the ever-changing regulatory landscape, optimize its operations for efficiency, and forge strategic partnerships that enhance its market reach.
